Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Liquidity (Details)

v3.10.0.1
Nature of Business and Liquidity (Details)
6 Months Ended
Jun. 30, 2018
candidate
project
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of drug technologies 3
Number of drug candidates 6
Number of drugs in clinical trials 2
Number of clinical trials 3
Number of other drug development projects | project 5
Number of recruitment sites 3
Number of operating segments | segment 1